Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Moderna, a pharmaceutical company, announces its dual flu and COVID-19 vaccine. Moderna has developed the mRNA-1083 and the test was conducted on participants 8,000 aged 50 and above. 

Moderna's dual flu and Covid-19 vaccine shows promising results in advanced trials

<h2>Moderna, a pharmaceutical company, announces its dual flu and COVID-19 vaccine. Moderna has developed the mRNA-1083 and the test was conducted on participants 8,000 aged 50 and above.&nbsp;</h2>

Moderna, a pharmaceutical company, announces that its dual flu and COVID-19 vaccine, designed to address both diseases with a single injection, has successfully completed a crucial phase of advanced scientific evaluations.
<h3>Moderna has developed the mRNA-1083</h3>
Moderna has developed the mRNA-1083, which will aid in protecting people from these serious illnesses. A test was conducted for this vaccine, involving over 8,000 participants aged 50 and above. Half of them received the combined vaccine, while the rest were administered separate vaccines for COVID-19 and flu.
When compared, the group receiving the combination vaccine produced 20% to 40% more antibodies against influenza strains and 30% more antibodies against COVID-19 variants. It is hoped that this vaccine will be available in the market by 2026.
<h3>Effective Against Most Influenza Strains</h3>
Research has indicated that the combined vaccine may have a longer shelf life. Additionally, mRNA technology has been used for the influenza component. This vaccine could be highly effective against most strains of influenza. It has shown effectiveness against both Influenza A group strains and Influenza B strains.
Prof John Tregoning, an immunologist at Imperial College London, said work on a dual vaccine was "a promising direction of travel", but that the science world awaited the full data for scrutiny.
Moderna is also developing an mRNA vaccine against a disease called cytomegalovirus, for which it hopes to have late-stage trial results this autumn.
Also watch:<a href="https://www.editorji.com/lifestyle-news/health/teenager-s-lung-punctures-after-vaping-for-weeks-know-how-harmful-e-cigarettes-can-be-1718020006309"> Teenager's lung punctures after vaping for weeks, know how harmful e cigarettes can be</a>

Will the present Covid-19 vaccines protect you against the Omicron variant of the virus that has created a global scare?
Well, scientists are studying the virus, but vaccine makers are already at work to adapt their shots to the virus that's considered to be highly infectious.
Pfizer, alongwith its partners BioNTech, plans to ship the new version of their shot within 100 days, Bloomberg has reported.
US-based vaccine maker Moderna expects a similar time-frame for a new vaccine tailored for 'Omicron'. It will possibly be available by early next year, Moderna's chief medical officer Paul Burton has told BBC.
Scientists, however, say they need more time to study the virus to come to any conclusion. There is still little clarity on its infectious nature, the severity of the disease it causes, and how well vaccines protect against it.
The World Health Organization said the overall risk from Omicron was "very high" and warned that any major surge would put pressure on health systems and cause more deaths.

Will we need new vaccines for Omicron? Here's what vaccine makers say

Omicron scare: Scientists are still studying the virus, but vaccine makers are already at work to adapt their shots to the new Covid variant

Vaccine makers are working to adapt their shots to Omicron

Will the present Covid-19 vaccines protect you against the Omicron variant of the virus that has created a global scare?
Well, scientists are studying the virus, but vaccine makers are already at work to adapt their shots to the virus that's considered to be highly infectious.
Pfizer, alongwith its partners BioNTech, plans to ship the new version of their shot within 100 days, Bloomberg has reported.
US-based vaccine maker Moderna expects a similar time-frame for a new vaccine tailored for 'Omicron'. It will possibly be available by early next year, Moderna's chief medical officer Paul Burton has told BBC.
Scientists, however, say they need more time to study the virus to come to any conclusion. There is still little clarity on its infectious nature, the severity of the disease it causes, and how well vaccines protect against it.
&nbsp;
&nbsp;
&nbsp;
&nbsp;

Omicron scare: Scientists are still studying the virus, but vaccine makers are already at work to adapt their shots to the new variant

Will the present Covid-19 vaccines protect you against the Omicron variant of the virus that has created a global scare?
Well, scientists are studying the virus, but vaccine makers are already at work to adapt their shots to the virus that's considered to be highly infectious.
Pfizer, alongwith its partners BioNTech, plans to ship the new version of their shot within 100 days, Bloomberg has reported.
US-based vaccine maker Moderna expects a similar time-frame for a new vaccine tailored for 'Omicron'. It will possibly be available by early next year, Moderna's chief medical officer Paul Burton has told BBC.
Scientists, however, say they need more time to study the virus to come to any conclusion. There is still little clarity on its infectious nature, the severity of the disease it causes, and how well vaccines protect against it.
The World Health Organization said the overall risk from Omicron was "very high" and warned that any major surge would put pressure on health systems and cause more deaths.
Also Watch:&nbsp;<a href="https://www.editorji.com/coronavirus/symptoms-unfamiliar-but-mild-doctor-who-detected-omicron-variant-1638207153909" target="_blank">Symptoms unfamiliar but mild: doctor who detected Omicron variant</a>

Japan's Okinawa region suspended the use of Moderna's Covid-19 vaccine on Sunday after another contamination was spotted.
It comes a day after the Japanese health ministry said it was investigating the death of two men who received shots from tainted Moderna batches -- though the cause of their death is unknown.
The Suspension came after the health ministry said two men, aged 30 and 38, died in early August after getting their second Moderna doses.
According to the reports, black substances were spotted in syringes and a vial, while pink substances were found in a different syringe filled with vaccine at the Okinawa centre.&nbsp;
"We are suspending the use of Moderna's Covid-19 vaccines as foreign substances were spotted in some of them," local government&nbsp;said in a statement.

Japan's Okinawa suspends Moderna shots after different substances were spotted in syringes

Japan's Okinawa region suspended the use of Moderna's Covid-19 vaccine after black substances were spotted in syringes and a vial

Japan's Okinawa halts use of&nbsp;Moderna doses over&nbsp;contaminants in some vials
Suspension came after two men&nbsp;died after getting their second Moderna doses
Local media: black substances were spotted in syringes and a vial
&nbsp;

<div class="highlighted-content">
It comes a day after the Japanese health ministry said it was investigating the death of two men who received shots from 'tainted'&nbsp;Moderna batches
</div>

Japan's Okinawa region suspended the use of Moderna's Covid-19 vaccine on Sunday after another contamination was spotted.
It comes a day after the Japanese health ministry said it was investigating the death of two men who received shots from tainted Moderna batches -- though the cause of their death is unknown.
The suspension came after the health ministry said two men, aged 30 and 38, died in early August after getting their second Moderna doses.
According to the reports, black substances were spotted in syringes and a vial, while pink substances were found in a different syringe filled with vaccine at the Okinawa centre.&nbsp;
"We are suspending the use of Moderna's Covid-19 vaccines as foreign substances were spotted in some of them," local government&nbsp;said in a statement.

Dr Poonam Khetrapal Singh, regional director of the World Health Organisation, South-East Asia, on Monday said that India has been offered 7.5 million doses of Moderna vaccine through the global health body&rsquo;s Covid-19 Vaccines Global Access (COVAX) programme.
However, there is no clarity so far when the jabs would be available in the country as WHO said that the availability is &ldquo;subject to clearance of indemnity clause.&rdquo;Last month, the Drugs Controller General of India had granted restricted emergency use authorisation to Moderna for its Covid-19 vaccine. The doses are to be imported by drug manufacturer Cipla, but will be under the purview of the govt.
Reports say, the Indian government has put forth certain conditions for finalising the indemnity clause contract and has sent it to the US drug manufacturer for their perusal.

WHO: India to get 7.5 million doses of Moderna jab via COVAX

WHO says India has been offered 7.5 million doses of Moderna jab via COVAX, but availability subject to finalising indemnity clause for import

WHO: India has been offered 7.5 million doses of Moderna vaccine via COVAX
No clarity on when the Moderna jabs would be available in India, says WHO
WHO: availability of Moderna&nbsp;vaccine subject to clearance of indemnity clause
Last month, the DCGI&nbsp;granted restricted emergency use authorisation to Moderna
Moderna&nbsp;vaccine&nbsp;to be imported by Cipla, but will be under govt purview&nbsp;
Reports: Govt&nbsp;finalising indemnity clause contract, sent it to US FDA&nbsp;

India has been offered 7.5 million doses of Moderna vaccine through WHO&rsquo;s COVAX programme. The availability of doses is subject to clearance of indemnity clause.

Dr Poonam Khetrapal Singh, regional director of the World Health Organisation, South-East Asia, on Monday said that India has been offered 7.5 million doses of Moderna vaccine through the global health body&rsquo;s Covid-19 Vaccines Global Access (COVAX) programme.
However, there is no clarity so far when the jabs would be available in the country as WHO said that the availability is &ldquo;subject to clearance of <a title="indemnity clause.&rdquo;" href="https://www.editorji.com/story/indemnity-what-is-it-what-do-pharma-majors-like-pfizer-moderna-sii-want-it-1622754907349">indemnity clause.&rdquo;</a>
Also watch:&nbsp;<a href="https://www.editorji.com/story/what-is-covid-19-r-factor-1626328730182">In Depth: What is Covid-19 'R' Factor?</a>
Last month, the Drugs Controller General of India had granted restricted emergency use authorisation to Moderna for its Covid-19 vaccine. The doses are to be imported by drug manufacturer Cipla&nbsp;but will be under the purview of the govt.
Reports say the Indian government has put forth certain conditions for finalising the indemnity clause contract and has sent it to the US drug manufacturer for their perusal.

Moderna&rsquo;s Covid-19 vaccine could reach India this week and be available in a few major government hospitals by July 15, Economic Times reported quoting Health officials.
While the mRNA-based&nbsp;vaccines developed by the US drugmaker may reach India this week only, the distribution to hospitals will take another week or so.
The Drugs Controller General of India had&nbsp;granted its approval to Mumbai-based pharmaceutical company Cipla to import Moderna&rsquo;s Covid-19 vaccine last month.&nbsp;

Moderna's Covid-19 vaccine in India this week

Get ready Moderna&nbsp;vaccine set to land in India in a week. Click below for details

Moderna's Covid vaccine in hospitals from July 15

Moderna&rsquo;s Covid-19 vaccine could reach India this week

Moderna&rsquo;s Covid-19 vaccine could reach India this week and be available in a few major government hospitals by July 15, ET reported quoting health officials.
While the mRNA-based&nbsp;vaccines developed by the US drugmaker may reach India this week only, the distribution to hospitals will take another week or so.
This is likely to make Moderna the fourth vaccine to be used in India after Covishield, Covaxin and Russia&rsquo;s Sputnik V. Cipla&nbsp;who is still to share details of the import plan for private use will not need separate approval as and when it works out a commercial deal with Moderna.&nbsp;

Drugmaker Moderna has said that its Covid vaccine produced protective antibodies against the delta variant that was first detected in India and has spread to many parts of the world.
Bloomberg has reported that Moderna researchers tested blood samples from eight people for antibodies against different coronavirus variants, including delta. The vaccine &ldquo;produced neutralizing titers against all variants tested,&rdquo; the company said in a statement.
India on Monday approved Moderna Covid vaccine for emergency use.
Moderna had earlier published research showing its vaccine produces neutralizing antibodies against the alpha, beta, and gamma variants that emerged in different regions.

Moderna says its Covid vaccine works against Delta variant

Drugmaker&nbsp;Moderna&nbsp;has said that its Covid&nbsp;vaccine produces antibodies against Dellta&nbsp;variant that was first detected in India

Moderna&nbsp;says its Covid&nbsp;vaccine works against Delta variant
Vaccine produced antibodies against Delta variant: Moderna
India approved Moderna&nbsp;Covid&nbsp;vaccine on Monday

Drugmaker&nbsp;Moderna&nbsp;has said that its Covid&nbsp;vaccine produces antibodies against Dellta&nbsp;variant that was first detected in India

Drugmaker Moderna has said that its Covid vaccine produced protective antibodies against the delta variant that was first detected in India and has spread to many parts of the world.
Bloomberg has reported that Moderna researchers tested blood samples from eight people for antibodies against different coronavirus variants, including delta. The vaccine &ldquo;produced neutralizing titers against all variants tested,&rdquo; the company said in a statement.
India on Monday approved Moderna Covid vaccine for emergency use.
Moderna had earlier published research showing its vaccine produces neutralizing antibodies against the alpha, beta, and gamma variants that emerged in different regions.

Cipla&nbsp;has got the nod from the DCGI&nbsp;to import Moderna's&nbsp;Covid&nbsp;19 vaccine into India as per reports.&nbsp;Cipla had sought DGCI's permission for importing and marketing authorisation of Moderna&rsquo;s coronavirus vaccine earlier on Tuesday.&nbsp;. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V.Moderna has proposed to launch a single-dose vaccine for the Indian market. Cipla&nbsp;has not yet confirmed a supply agreement with Moderna&nbsp;though the company said the logistics and storage are already in place for importing the vaccine.&nbsp;Moderna&nbsp; has an&nbsp;mRNA-based vaccine with an efficacy rate of 94.1 percent, according to WHO estimate.

Cipla gets nod to import Moderna Covid 19 vaccine

Gear up for vaccine number 4, Drug regulator gives Cipla&nbsp;the nod to import Moderna's&nbsp;Covid&nbsp;19 vaccine

Vaccine No. 4 is here 

Cipla&nbsp;has got the nod from the DCGI&nbsp;to import Moderna's&nbsp;Covid&nbsp;19 vaccine into India as per reports.&nbsp;
Cipla had sought DGCI's permission for importing and marketing authorisation of Moderna&rsquo;s coronavirus vaccine earlier on Tuesday.&nbsp;. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V.
Moderna has proposed to launch a single-dose vaccine for the Indian market. Cipla&nbsp;has not yet confirmed a supply agreement with Moderna&nbsp;though the company said the logistics and storage are already in place for importing the vaccine.&nbsp;
Moderna&nbsp; has an&nbsp;mRNA-based vaccine with an efficacy rate of 94.1 percent, according to WHO estimate.

Drugs Controller General of India&rsquo;s (DCGI) has give the nod to import Moderna's COVID-19 vaccine for restricted emergency use in India.&nbsp;

Cipla&nbsp;has got the nod from the DCGI&nbsp;to import Moderna's&nbsp;Covid&nbsp;19 vaccine into India.&nbsp; Cipla had sought DGCI's permission for importing and marketing authorisation of Moderna&rsquo;s coronavirus vaccine earlier on Tuesday.&nbsp;. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V. Moderna has proposed to launch a single-dose vaccine for the Indian market. Cipla&nbsp;has not yet confirmed a supply agreement with Moderna&nbsp;though the company said the logistics and storage are already in place for importing the vaccine.&nbsp; Moderna&nbsp; has an&nbsp;mRNA-based vaccine with an efficacy rate of 94.1 percent, according to WHO estimate. Read Also: <a href="https://www.edtr.ai/9q00">Why Covishield&nbsp;is not on the vaccine passport list for EU</a>

CDC safety group said there&rsquo;s a &ldquo;likely association&rdquo; between rare heart inflammation mostly in people 30 and under who received Pfizer&rsquo;s or Moderna&rsquo;s Covid-19 vaccine.&nbsp;There have been more than 1,200 cases of a myocarditis or pericarditis&nbsp;as per data collected by CDC&nbsp;which translated to a link of&nbsp;12.6 heart inflammation cases per million doses of Pfizer/Moderna&nbsp;vaccines.&nbsp;Myocarditis is the inflammation of the heart muscle, while pericarditis is the inflammation of the membrane surrounding the heart."CDC&nbsp;officials are gathering more data to fully understand the potential risks, how to manage it and whether there are any long-term issues," said&nbsp;Dr. Grace Lee, who chairs the CDC's safety group. She also highlighted that, "Clinical presentation of myocarditis cases following vaccination has been distinct, occurring most often within one week after dose two, with chest pain as the most common presentation.&rdquo;&nbsp;The agency said there have been 267 cases of myocarditis or pericarditis reported after receiving one dose of the Pfizer&rsquo;s or Moderna&rsquo;s Covid-19 vaccines and 827 reported cases after two doses through June 11. There are 132 additional cases where the number of doses received is unknown, the CDC said.

CDC warns of heart inflammation concerns after Pfizer, Moderna vaccine shot for young people

CDC&nbsp;group warns of rare heart inflammation in young people after Pfizer, Moderna&nbsp;Covid shot

<ul>
<li>CDC&nbsp;safety group: Likely link between Pfizer/Moderna&nbsp;vaccine and heart condition&nbsp;</li>
<li>1,200 cases of a myocarditis/pericarditis mostly in people under 30 after vaccine: CDC</li>
<li>Myocarditis is the inflammation of the heart muscle</li>
<li>CDC&nbsp;safety group: Gathering more data to understand long term issues</li>
<li>Chest pain the most common signal post dose two for heart issue</li>
</ul>

America's Centre for Disease Control has said there&rsquo;s a &ldquo;likely association&rdquo; between rare heart inflammation mostly in people 30 and under who received Pfizer&rsquo;s or Moderna&rsquo;s Covid-19 vaccine.&nbsp;There have been more than 1,200 cases of a myocarditis or pericarditis&nbsp;as per data collected by CDC&nbsp;which translated to a link of&nbsp;12.6 heart inflammation cases per million doses of Pfizer/Moderna&nbsp;vaccines.&nbsp; Myocarditis is the inflammation of the heart muscle, while pericarditis is the inflammation of the membrane surrounding the heart. "CDC&nbsp;officials are gathering more data to fully understand the potential risks, how to manage it and whether there are any long-term issues," said&nbsp;Dr. Grace Lee, who chairs the CDC's safety group.
She also highlighted that, "Clinical presentation of myocarditis cases following vaccination has been distinct, occurring most often within one week after dose two, with chest pain as the most common presentation.&rdquo;&nbsp; The agency said there have been 267 cases of myocarditis or pericarditis reported after receiving one dose of the Pfizer&rsquo;s or Moderna&rsquo;s Covid-19 vaccines and 827 reported cases after two doses through June 11. There are 132 additional cases where the number of doses received is unknown, the CDC said.

Covid-19 vaccine Covishield maker Serum Institute of India (SII) has demanded indemnity from liability, reports said quoting sources, adding not just SII but &lsquo;all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it&rsquo;.&nbsp;
This comes amid reports that India might grant indemnity to foreign drug companies such as Pfizer and Moderna. &nbsp;
Indemnity from liability is a key condition put forth by vaccine-makers Pfizer and Moderna for supplying their Covid shots to India. Pfizer has immunity in countries like the US where it cannot be sued for any adverse effects.&nbsp;
The government has not given any manufacturer indemnity or protection against legal action for any severe side effects so far.&nbsp;
What is indemnity and why are Covid vaccine makers seeking it?&nbsp;
With all the buzz around indemnity demand, one might wonder about the relevance of the term and why vaccine makers are pressing for it.&nbsp;
Indemnity is a sort of protection that pharma companies seek to shield themselves from potential compensation demands from those who may experience adverse effects after getting vaccinated.&nbsp;
Indemnity is like granting a concessional request of legal defence from any claims associated with the use of companies' COVID vaccines in India&nbsp;
When a pharma company has indemnity granted by the government of the country it is operating, it means it cannot be sued for negligence related to administering the vaccine. &nbsp;
The company will not be liable to answer if someone suffers side effects and decides to take the matter to court. The government will instead have to become the respondent there.&nbsp;
What is the status in other countries?&nbsp;
Both Pfizer and Moderna have received protection against lawsuits through indemnity clauses for their Covid-19 vaccines in other countries, including the US and Brazil. &nbsp;
The vaccines developed by Pfizer and Moderna work on the same technology and they have proved to be more than 90 per cent effective against Covid-19. Also, these vaccines have been approved in more than 40 countries.&nbsp;
Will they? Will they not?&nbsp;
The Health Ministry, citing other countries have reportedly said and "there is no problem" in granting indemnity or legal protection from any claims linked to the use of a company's COVID-19 vaccine.&nbsp;&nbsp;The Health Ministry sources further said that indemnity can be given if foreign pharma companies have applied for Emergency Use Authorisation in India.&nbsp;
Pfizer and Moderna have said they will export their COVID-19 vaccines to India only if the company is guarded against legal cases.&nbsp;
In February this year, Pfizer became the first foreign drugmaker to apply for emergency use approval of its vaccine candidate in India, but the application was later withdrawn. Later, in May Pfizer said it is holding fresh talks with the Indian government.&nbsp;&nbsp;Pfizer&rsquo;s spokesperson stressed that the safety and efficacy data of the vaccine had been backed by regulatory authorities in US, Britain, Japan and the World Health Organization.&nbsp;
In the wake of acute shortage of COVID-19 vaccine, the Centre has been strongly criticised for its vaccination policy. The government halted the exports of coronavirus vaccine shots earlier given under its "Vaccine Maitri" programme and scrambled to procure more jabs to address the shortage. In this scenario it looks likely that it will grant indemnity to Pfizer, Moderna, and SII to expedite the vaccination process in the country.&nbsp;
The government will look at the indemnity clause &lsquo;on the basis of practices followed internationally&rsquo;, sources said.&nbsp;

Indemnity: What is it? What do pharma majors like Pfizer, Moderna & SII want it?

Covid-19 vaccine Covishield maker Serum Institute of India (SII) has demanded indemnity from liability, reports said quoting sources, adding not just SII but &lsquo;all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it&rsquo;.&nbsp;
 This comes amid reports that India might grant indemnity to foreign drug companies such as Pfizer and Moderna. &nbsp;
Indemnity from liability is a key condition put forth by vaccine-makers Pfizer and Moderna for supplying their Covid shots to India. Pfizer has immunity in countries like the US where it cannot be sued for any adverse effects.&nbsp;
The government has not given any manufacturer indemnity or protection against legal action for any severe side effects so far.&nbsp;
What is indemnity and why are Covid vaccine makers seeking it?&nbsp;
With all the buzz around indemnity demand, one might wonder about the relevance of the term and why vaccine makers are pressing for it.&nbsp;
Indemnity is a sort of protection that pharma companies seek to shield themselves from potential compensation demands from those who may experience adverse effects after getting vaccinated.&nbsp;
Indemnity is like granting a concessional request of legal defence from any claims associated with the use of companies' COVID vaccines in India&nbsp;
When a pharma company has indemnity granted by the government of the country it is operating, it means it cannot be sued for negligence related to administering the vaccine. &nbsp;
The company will not be liable to answer if someone suffers side effects and decides to take the matter to court. The government will instead have to become the respondent there.&nbsp;
What is the status in other countries?&nbsp;
Both Pfizer and Moderna have received protection against lawsuits through indemnity clauses for their Covid-19 vaccines in other countries, including the US and Brazil. &nbsp;
The vaccines developed by Pfizer and Moderna work on the same technology and they have proved to be more than 90 per cent effective against Covid-19. Also, these vaccines have been approved in more than 40 countries.&nbsp;
Will they? Will they not?&nbsp;
The Health Ministry, citing other countries have reportedly said and "there is no problem" in granting indemnity or legal protection from any claims linked to the use of a company's COVID-19 vaccine.&nbsp;&nbsp;The Health Ministry sources further said that indemnity can be given if foreign pharma companies have applied for Emergency Use Authorisation in India.&nbsp;
Pfizer and Moderna have said they will export their COVID-19 vaccines to India only if the company is guarded against legal cases.&nbsp;
In February this year, Pfizer became the first foreign drugmaker to apply for emergency use approval of its vaccine candidate in India, but the application was later withdrawn. Later, in May Pfizer said it is holding fresh talks with the Indian government.&nbsp;&nbsp;Pfizer&rsquo;s spokesperson stressed that the safety and efficacy data of the vaccine had been backed by regulatory authorities in US, Britain, Japan and the World Health Organization.&nbsp;
In the wake of acute shortage of COVID-19 vaccine, the Centre has been strongly criticised for its vaccination policy. The government halted the exports of coronavirus vaccine shots earlier given under its "Vaccine Maitri" programme and scrambled to procure more jabs to address the shortage. In this scenario it looks likely that it will grant indemnity to Pfizer, Moderna, and SII to expedite the vaccination process in the country.&nbsp;
The government will look at the indemnity clause &lsquo;on the basis of practices followed internationally&rsquo;, sources said.&nbsp;

Covid-19 vaccine Covishield maker Serum Institute of India (SII) has demanded indemnity from liability, reports said quoting sources. The SII&nbsp;said &lsquo;all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it&rsquo;.&nbsp;
 This comes amid reports that India might grant indemnity to foreign drug companies such as Pfizer and Moderna. &nbsp;
Indemnity from liability is a key condition put forth by vaccine-makers Pfizer and Moderna for supplying their Covid shots to India. Pfizer has immunity in countries like the US where it cannot be sued for any adverse effects.&nbsp;
The government has not given any manufacturer indemnity or protection against legal action for any severe side effects so far.&nbsp;
What is indemnity and why are Covid vaccine makers seeking it?&nbsp;
With all the buzz around indemnity demand, one might wonder about the relevance of the term and why vaccine makers are pressing for it.&nbsp;
Indemnity is a legal clause mostly used by insurance companies and claims companies to seek to shield themselves from potential compensation demands from those who may experience adverse effects after getting vaccinated.&nbsp;
Indemnity is like granting a concessional request of legal defence from any claims associated with the use of companies' COVID vaccines in India&nbsp;
When a pharma company has indemnity granted by the government of the country it is operating, it means it cannot be sued for negligence related to administering the vaccine. &nbsp;
The company will not be liable to answer if someone suffers side effects and decides to take the matter to court. The government will instead have to become the respondent there.&nbsp;
What is the status in other countries?&nbsp;
Both Pfizer and Moderna have received protection against lawsuits through indemnity clauses for their Covid-19 vaccines in other countries, including the US and Brazil. &nbsp;
The vaccines developed by Pfizer and Moderna work on the same technology and they have proved to be more than 90 per cent effective against Covid-19. Also, these vaccines have been approved in more than 40 countries.&nbsp;
Will they? Will they not?&nbsp;
The Health Ministry, citing other countries have reportedly said and "there is no problem" in granting indemnity or legal protection from any claims linked to the use of a company's COVID-19 vaccine.&nbsp;&nbsp;The Health Ministry sources further said that indemnity can be given if foreign pharma companies have applied for Emergency Use Authorisation in India.&nbsp;
Pfizer and Moderna have said they will export their COVID-19 vaccines to India only if the company is guarded against legal cases.&nbsp;
In February this year, Pfizer became the first foreign drugmaker to apply for emergency use approval of its vaccine candidate in India, but the application was later withdrawn. Later, in May Pfizer said it is holding fresh talks with the Indian government.&nbsp;&nbsp;Pfizer&rsquo;s spokesperson stressed that the safety and efficacy data of the vaccine had been backed by regulatory authorities in US, Britain, Japan and the World Health Organization.&nbsp;
In the wake of acute shortage of COVID-19 vaccine, the Centre has been strongly criticised for its vaccination policy. The government halted the exports of coronavirus vaccine shots earlier given under its "Vaccine Maitri" programme and scrambled to procure more jabs to address the shortage. In this scenario it looks likely that it will grant indemnity to Pfizer, Moderna, and SII to expedite the vaccination process in the country.&nbsp;
The government will look at the indemnity clause &lsquo;on the basis of practices followed internationally&rsquo;, sources said.&nbsp;

Amid reports that the govt may be inclined to grant indemnity from liability to foreign drug companies such as Pfizer and Moderna, Serum Institute of India has also demanded the same, reports said quoting sources. "Not just Serum Institute of India, all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it," reports said quoting Serum sources. Serum Institute is producing AstraZeneca's Covishield vaccine.Indemnity from liability is a key condition put forth by vaccine-makers Pfizer and Moderna for supplying their Covid shots to India.The govt has so far not given such a relaxation to any vaccine maker.

'Same rules': Serum Institute too seeks indemnity protection, say reports

Amid reports that the govt may be inclined to grant indemnity from liability to foreign drug companies such as Pfizer and Moderna, Serum Institute of India has also demanded the same: reports

'Same rules': Serum too seeks indemnity protection, say reports

Amid reports that the govt may be inclined to grant indemnity from liability to foreign drug companies such as Pfizer and Moderna, Serum Institute of India has also demanded the same, reports said quoting sources. "Not just Serum Institute of India, all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it," reports said quoting Serum sources. Serum Institute is producing AstraZeneca's Covishield vaccine. Indemnity from liability is a key condition put forth by vaccine-makers Pfizer and Moderna for supplying their Covid shots to India. The govt has so far not given such a relaxation to any vaccine maker.

The indemnity roadblock set to be removed paving the way for Pfizer, Moderna&nbsp;vaccines to be imported into India. Reports indicate that the govt is gearing to grant indemnity&nbsp;from legal liability to the pharma&nbsp;giants.&nbsp;Pfizer who has stated that they have 5 crore&nbsp;doses ready to be imported into India had demanded an indemnity clause to finalise the deal. Such a clause absolves the pharma&nbsp;major from any legal liability in case of any adverse effects. Cipla also had approached the govt seeking the same for Moderna&nbsp;as the company is looking to import 50 million doses of the vaccine as they become available.&nbsp;

Indemnity roadblock set to be removed, paving the way for Pfizer

Indemnity roadblock set to be removed, paving the way for Pfizer vaccine

The indemnity roadblock set to be removed paving the way for Pfizer, Moderna&nbsp;vaccines to be imported into India. Reports indicate that the govt is gearing to grant indemnity&nbsp;from legal liability to the pharma&nbsp;giants.&nbsp; Pfizer who has stated that they have 5 crore&nbsp;doses ready to be imported into India had demanded an indemnity clause to finalise the deal. Such a clause absolves the pharma&nbsp;major from any legal liability in case of any adverse effects. Cipla also had approached the govt seeking the same for Moderna&nbsp;as the company is looking to import 50 million doses of the vaccine as they become available.&nbsp;

Pharma giant Cipla is set to commit $1 billion in importing Moderna vaccines into India but is awaiting clarity from the government. PTI reports that Cipla is seeking fast track approvals to bring Moderna's single-dose COVID-19 booster vaccine&nbsp;but is seeking waivers from the government of key clauses. As per unnamed sources&nbsp; to PTI Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty. Cipla has shown interest to procure 50 million doses from Moderna for 2022. Cipla has sought the government's assurance that no price capping would apply for imported vaccines to be provided through private hospitals and that the booster vaccine can be covered under the liberalised pricing policy and kept exempt from any price capping.&nbsp;

Cipla to import $1 billion of Moderna vaccine, seeks clarity from govt

Cipla to import $1 billion of Moderna vaccine, seeks clarity from govt on price capping, bridge trials and the stick indemnity.&nbsp;

Vaccine Update

Pharma giant Cipla is set to commit $1 billion in importing Moderna vaccines into India but is awaiting clarity from the government. PTI reports that Cipla is seeking fast track approvals to bring Moderna's single-dose COVID-19 booster vaccine&nbsp;but is seeking waivers from the government of key clauses. As per unnamed sources&nbsp; to PTI Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty. Cipla has shown interest to procure 50 million doses from Moderna for 2022. Cipla has sought the government's assurance that no price capping would apply for imported vaccines to be provided through private hospitals and that the booster vaccine can be covered under the liberalised pricing policy and kept exempt from any price capping.&nbsp;

Pharma&nbsp;giant Pfizer is set to provide India with 5 crore&nbsp;vaccine doses this year itself but wants the indemnity concern to be resolved.&nbsp;PTI reports that as per sources Pfizer wants&nbsp;significant regulatory relaxations including indemnification which absolves the company of any legal liability incase of a adverse after effect.&nbsp;
In a high-level meeting attended by members&nbsp;Ministry of External Affairs, NITI Aayog, Department of Biotechnology, Law Ministry and Health Ministry the options of procuring more vaccines was discussed.&nbsp;
Sources have told PTI&nbsp;that&nbsp;Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021 and there are limited prospects of Johnson &amp; Johnson exporting its jabs from the US to other countries in the near future.

Pfizer set with 5 crore vaccine doses for India but legal hurdle remains

Pfizer set with 5 crore doses for India but legal hurdle remains, Moderna and J&amp;J unlikely this year.

The Vaccine Update

<ul>
<li>Pfizer set to provide 5 crore&nbsp;vaccine doses to India&nbsp;</li>
<li>Pfizer demands regulatory relaxations before exporting jabs</li>
<li>Pfizer continues to demand indemnity before providing vaccine</li>
<li>Govt holds high level meet to discuss vaccine availability</li>
<li>Moderna indicates all jabs booked up for this year</li>
<li>J&amp;J unlikely to export any vaccines from US this year&nbsp;</li>
</ul>

Pharma&nbsp;giant Pfizer is set to provide India with 5 crore&nbsp;vaccine doses this year itself but wants the indemnity concern to be resolved.&nbsp; PTI reports that as per sources Pfizer wants&nbsp;significant regulatory relaxations including indemnification which absolves the company of any legal liability incase of a adverse after effect.&nbsp;
In a high-level meeting attended by members&nbsp;Ministry of External Affairs, NITI Aayog, Department of Biotechnology, Law Ministry and Health Ministry the options of procuring more vaccines was discussed.&nbsp;
Sources have told PTI&nbsp;that&nbsp;Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021 and there are limited prospects of Johnson &amp; Johnson exporting its jabs from the US to other countries in the near future.

Delhi Chief Minister Arvind Kejriwal on Monday said that drug majors Pfizer and Moderna have "refused to sell vaccines" to the state government. He further added that the vaccine manufacturers have said they will deal with the central government directly. Kejriwal once again appealed to the centre to import vaccines and distribute to the states.
His remarks come a day after Punjab said US pharmaceutical giant Moderna refused to sell vaccines to the state directly.
Amid vaccine shortage, Kejriwal said on Saturday that his government was compelled to pause the roll-out for 18-44 age group.

Delhi CM: Pfizer, Moderna said won’t sell vaccine to state, will only deal with Centre 

<ul>
<li>Delhi CM: Pfizer, Moderna&nbsp;refused to sell vaccine to state govt</li>
<li>CM: Phizer, Moderna&nbsp;said will deal with the Centre</li>
<li>Kejriwal appealed to Centre to import &amp; distribute vaccines</li>
<li>Amid shortage, Delhi govt paused vaccination for 18-44 age group</li>
</ul>

Delhi Chief Minister Arvind Kejriwal on Monday said that drug majors Pfizer and Moderna have "refused to sell vaccines" to the state government. He further added that the vaccine manufacturers have said they will deal with the central government directly. Kejriwal once again appealed to the centre to import vaccines and distribute to the states.
His remarks come a day after Punjab said US pharmaceutical giant Moderna refused to sell vaccines to the state directly.
Amid vaccine shortage, Kejriwal said on Saturday that his government was compelled to pause the roll-out for 18-44 age group.

Covid-19 vaccine manufacturer Moderna Inc declined Punjab government&rsquo;s request to procure vaccines.
Punjab nodal officer Vikas Garg said in a statement on Saturday that Moderna refused to send vaccines to the state government citing their policy which outlines that the company will only deal with the Centre. The statement highlighted that the Punjab government approached Sputnik V, Pfizer, Moderna, and Johnson &amp; Johnson after being directed by the chief minister Captain Amarinder Singh. It also pointed out that the state government was forced to stop vaccinations due to unavailability of vaccines for the last three days.

Moderna refuses to send vaccines to Punjab, says it only deals with Centre

Covid-19 vaccine manufacturer Moderna Inc declined Punjab government&rsquo;s request to procure vaccines.
Punjab nodal officer Vikas Garg said in a statement on Saturday that Moderna refused to send vaccines to the state government citing their policy which outlines that the company will only deal with the Centre. The statement highlighted that the Punjab government approached Sputnik V, Pfizer, Moderna, and Johnson &amp; Johnson after being directed by the chief minister Captain Amarinder Singh. It also pointed out that the state government was forced to stop vaccinations due to unavailability of vaccines for the last three days.

Covid-19 vaccine manufacturer Moderna Inc declined Punjab government&rsquo;s request to procure vaccines.
Punjab nodal officer Vikas Garg said in a statement on Saturday that Moderna refused to send vaccines to the state government citing their policy which outlines that the company will only deal with the Centre. The statement highlighted that the Punjab government approached Sputnik V, Pfizer, Moderna, and Johnson &amp; Johnson after being directed by the chief minister Captain Amarinder Singh. It also pointed out that the state government was forced to stop vaccinations due to unavailability of vaccines for the last three days.

96% efficacy, that's the word coming in from&nbsp;Moderna&nbsp;on Thursday it declared the results of its first clinical trials of it's&nbsp;Covid-19 vaccine among youths aged 12 to 17.With a trial pool of&nbsp;3,235 participants in the United States, it detected only 12 cases of coronavirus 14 days after the first shot. For these intermediate results, participants were followed up on average 35 days after the second injection. Moderna&nbsp;also claimed that any side effects had been "mild or moderate in severity," most commonly pain at the injection site.
Pfizer has already applied for authorization of their own vaccine for 12-15 year olds in the United States and Europe. On Wednesday, Canada became the first country to authorize the Pfizer shot for this age group.
&nbsp;

Rush to vaccine children Moderna releases clinical trial efficacy results in 12-17 year olds

Moderna releases clinical trial efficacy results in 12-17 year olds, claims moderate side effects.&nbsp;

Rush to vaccine children 

<ul>
<li>Moderna&nbsp;trial shows 96% efficacy in vaccine for 12-17 year old</li>
<li>2/3 of 3,235 participants in trials in US&nbsp;received the vaccine&nbsp;</li>
<li>No severe side effect observed in trial for 12-17 year old: Moderna</li>
<li>Pfizer has sought&nbsp;approval for vaccine use for 12-15 in US, Europe</li>
<li>Canada&nbsp; first country to authorises Pfizer vaccine for 12-15 year age</li>
</ul>

96% efficacy, that's the word coming in from&nbsp;Moderna&nbsp;on Thursday it declared the results of its first clinical trials of it's&nbsp;Covid-19 vaccine among youths aged 12 to 17. With a trial pool of&nbsp;3,235 participants in the United States, it detected only 12 cases of coronavirus 14 days after the first shot. For these intermediate results, participants were followed up on average 35 days after the second injection. Moderna&nbsp;also claimed that any side effects had been "mild or moderate in severity," most commonly pain at the injection site.
Pfizer has already applied for authorization of their own vaccine for 12-15 year olds in the United States and Europe. On Wednesday, Canada became the first country to authorize the Pfizer shot for this age group.
&nbsp;

Moderna CEO on Thursday said new coronavirus strains are likely to emerge and countries will be required to get booster shots of the two-dose covid-19 vaccine as the southern hemisphere heads toward winter months from June. 
Speaking on a panel on CNBC, Stephane Bancel said, that over the next six months, as the Southern Hemisphere enters the fall and winter, we could see more variants of concern emerge, adding that booster shots will be needed as the virus is not going anywhere.
The comment comes a day after Moderna announced that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19 first found in Brazil and South Africa.

New Covid strains will emerge in 6 months, will need booster shots: Moderna CEO

New Covid strains will emerge in 6 months, people will need booster shots, warns&nbsp;Moderna CEO

//&nbsp;Moderna&nbsp;CEO: virus here to stay,&nbsp;new strains likely in next 6 months // 'More Covid strains probable as Southern Hemisphere enters winter' // 'Countries will be required to get booster shots of the vaccine' //&nbsp;Moderna:&nbsp;3rd shot of its jab increases immunity against variants&nbsp;

Moderna CEO on Thursday said new coronavirus strains are likely to emerge and countries will be required to get booster shots of the two-dose covid-19 vaccine as the southern hemisphere heads toward winter months from June.
Speaking on a panel on CNBC, Stephane Bancel said, that over the next six months, as the Southern Hemisphere enters the fall and winter, we could see more variants of concern emerge, adding that booster shots will be needed as the virus is not going anywhere.
The comment comes a day after Moderna announced that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19, first found in Brazil and South Africa.

Tata Group's healthcare arm is said to have started initial discussions with drugmaker Moderna to launch its Covid-19 vaccine in India, the Economic Times has reported. Tata Medical &amp; Diagnostics could team up with the India's Council of Scientific and Industrial Research to carry out clinical trials of Moderna's vaccine candidate in India, the report said. Unlike Pfizer's vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna's can be stored at normal fridge temperatures, making it more suited for India. Moderna's late-stage study showed it was 94.1% effective with no serious safety concerns.

Tata in talks with Moderna to launch its Covid vaccine in India: report

Tata Group's healthcare arm is said to have started initial discussions with drugmaker Moderna to launch its Covid-19 vaccine in India, says report

Tata in talks with Moderna to launch its Covid vaccine in India

Tata Group's healthcare arm is said to have started initial discussions with drugmaker Moderna to launch its Covid-19 vaccine in India, the Economic Times has reported. Tata Medical &amp; Diagnostics could team up with the India's Council of Scientific and Industrial Research to carry out clinical trials of Moderna's vaccine candidate in India, the report said. Unlike Pfizer's vaccine, which must be kept at minus 70 degrees Celsius or below, Moderna's can be stored at normal fridge temperatures, making it more suited for India. Moderna's late-stage study showed it was 94.1% effective with no serious safety concerns.

Moderna's Covid-19 vaccine is likely to offer protection of up to a couple of years from the virus, its chief executive said on Thursday, news agency Reuters has reported. He, however, added that more data is still needed to make a definitive assessment. "The antibody decay generated by the vaccine in humans goes down very slowly...We believe there will be protection potentially for a couple of years," Moderna CEO Stephane Bancel has said. He added that his company was about to prove that its vaccine would also be effective against variants of the coronavirus seen in Britain and South Africa. Given vaccines development and pharmacovigilance usually requires years, the protection duration of COVID-19 shots is a lingering question for scientists and regulators.
&nbsp;

Moderna Covid vaccine likely to protect for a couple of years: CEO

Moderna's Covid-19 vaccine is likely to offer protection of up to a couple of years from the virus, its chief executive has said

Moderna's Covid-19 vaccine is likely to offer protection of up to a couple of years from the virus, its chief executive said on Thursday, news agency Reuters has reported. He, however, added that more data is still needed to make a definitive assessment. "The antibody decay generated by the vaccine in humans goes down very slowly...We believe there will be protection potentially for a couple of years," Moderna CEO Stephane Bancel has said. He added that his company was about to prove that its vaccine would also be effective against variants of the coronavirus seen in Britain and South Africa.

Moderna's Covid-19 vaccine is likely to offer protection of up to a couple of years from the virus, its chief executive said on Thursday, news agency Reuters has reported. He, however, added that more data is still needed to make a definitive assessment. "The antibody decay generated by the vaccine in humans goes down very slowly...We believe there will be protection potentially for a couple of years," Moderna CEO Stephane Bancel has said. He added that his company was about to prove that its vaccine would also be effective against variants of the coronavirus seen in Britain and South Africa. Given vaccines development and pharmacovigilance usually requires years, the protection duration of COVID-19 shots is a lingering question for scientists and regulators.
&nbsp;

A US panel of experts on Thursday voted to recommend emergency approval of Moderna's Covid-19 vaccine. It paves the way for six million doses to start shipping as soon as this weekend. The Food and Drug Administration is now expected to imminently grant an emergency use authorization, which would make Moderna's vaccine the second to be approved. The United States this week started Covid vaccination amid piling virus deaths after Pfizer vaccine was cleared for emergency use.

Moderna Covid vaccine close to US govt nod

A US panel of experts on Thursday voted to recommend emergency approval of Moderna's Covid-19 vaccine. It will&nbsp;the second vaccine to be approved after Pfizer

A US panel of experts on Thursday voted to recommend emergency approval of Moderna's Covid-19 vaccine. It paves the way for six million doses to start shipping as soon as this weekend. The Food and Drug Administration is now expected to imminently grant an emergency use authorization, which would make Moderna's vaccine the second to be approved. The United States this week started Covid vaccination amid piling virus deaths after Pfizer vaccine was cleared for emergency use.

moderna

Categories